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Infections involving cardiovascular implantable electronic
devices (CIEDs) remain an unfortunate indication for
repeated device-related procedures, including extractions
and reimplantations.1 Recurrent infections involving trans-
venous leads and superﬁcial device pockets may eventually
lead to epicardial lead implantation and generator placement
in deeper tissue planes, both of which require a more
invasive surgical approach. We present a unique case of a
patient with recurrent CIED-related pocket infections involv-
ing both transvenous and epicardial pacing systems that was
ultimately addressed with implantation of an investigational
leadless cardiac pacemaker.Case report
A 35-year-old patient with congenital complete heart block
and Hansen’s disease (leprosy, infection with Mycobacte-
rium leprae) has been followed for years in our institution’s
device program. While the patient’s conduction disorder
resulted in pacemaker dependency, the coexisting Hansen’s
disease resulted in extreme skin and soft tissue fragility,
which predisposed to skin breakdown, device erosion,
secondary bacterial infections, and sepsis (Figure 1).
The patient had prior transvenous pacing systems and
leads, all of which became infected following pocket site
breakdown and subsequent bacteremia and sepsis. Each
occurrence was managed in accordance with accepted treat-
ment guidelines. Multiple reimplantations with transvenous
systems at alternate sites ensued following initial infection
clearance, only to require explant owing to repeated infec-
tions. Eventually, a single-chamber (VVI) epicardial pacing
system was implanted with special attention given to
implanting the pulse generator and proximal lead slack
under the rectus muscle. This system unfortunately suffered
a similar fate as prior pacemakers, necessitating surgicalKEYWORDS Cardiovascular implantable electronic devices; Infection
(Heart Rhythm Case Reports 2016;2:339–341)
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tions with appropriate antimicrobial therapy, and to reduce
risk of developing antibiotic-resistant organisms, chronic
prophylactic antibiotic therapy was never recommended.
Further consideration of surgical epicardial device reimplan-
tation was deferred in favor of exploring alternative manage-
ment strategies. Conservative management without device
reimplantation was not considered suitable, given the
patient’s baseline wide complex escape rhythm of only 20
beats per minute. In a chronic VVI paced state, transthoracic
echocardiogram demonstrated a left ventricular ejection
fraction of 45%–50%. The Nanostim leadless cardiac pace-
maker (St Jude Medical, Sylmar, CA) was proposed as the
best option for providing permanent pacing support with
theoretically less risk of CIED infection, given that the
pacemaker is entirely conﬁned to the right ventricular (RV)
cavity without communication with the skin or superﬁcial
soft tissues.
Given that the device was still under investigational study
(NIH clinical trial identiﬁer NCT02030418), as well as the
proposed off-label indication for its implantation in this case,
compassionate use approval was requested from the U.S.
Food and Drug Administration and our local institutional
review board to implant the leadless pacemaker in this
patient. While awaiting approval, the patient was supported
with temporary pacing systems using a traditional active
ﬁxation pacing electrode connected to an external pulse
generator. Allergy skin testing to standard pacemaker
component materials including nickel was also performed
to conﬁrm absence of an allergic response as a possible
explanation for the patient’s condition.
After compassionate use approval was received, the
patient underwent standard implantation of the leadless
pacemaker without complication (Figure 2). The device
was implanted using its delivery ensemble via the right
femoral vein following contrast injections demonstrating
lower systemic venous patency and RV cavity size and
borders. The device was ﬁxated and deployed at the apical
RV septum. Initial pacing threshold was 0.75 volts at 0.4 ms
pulse width with an impedance of 600 ohms. Sensed native
escape rhythm R waves were 12 mV in amplitude. The
device was programmed to a VVIR mode at 60 beats perpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.03.011
Figure 2 Fluoroscopic image of ﬁnal leadless pacemaker position at the
distal septal aspect of the right ventricular cavity. A retained fragment of a
previously placed (and subsequently removed) epicardial pacing lead is also
present.
KEY TEACHING POINTS
 Infections involving cardiovascular implantable
electronic devices (CIEDs) remain a challenging
problem causing signiﬁcant morbidity, mortality,
and need for reintervention in recipients.
 The leadless pacemaker provides reliable single-
chamber pacing while eliminating complications
related to transvenous leads and reducing infection
risks, given its placement entirely within the heart.
 Implanting physicians should be aware of scenarios
where novel CIED technologies can potentially be
applied to address unusual circumstances and
complications.
Heart Rhythm Case Reports, Vol 2, No 4, July 2016340minute, and the patient was discharged home on postproce-
dure day 1. On subsequent ambulatory visits, pacing function
and device location have remained satisfactory, with an
excellent pacing threshold of 0.5 V at 0.4 ms at 1 year
postimplantation. The patient has shown no evidence of
cutaneous or systemic infection and has resumed all normal
activity.Discussion
The presented case represents a highly unusual and rare set
of circumstances in a patient requiring permanent pacemaker
support. Conventional approaches to addressing and circum-
venting recurrent CIED infections, speciﬁcally involving the
device pocket, were not effective in preventing repeated
occurrences, given a primary infectious and dermatologic
condition that predisposed to secondary bacterial infections.
Repeated infections were not due to poor implantationFigure 1 Photograph of patient’s chest and abdomen demonstrating
signiﬁcant scarring in both the left and right chest walls and abdomen from
prior pacemaker implantation and removal secondary to recurrent device
erosions and infections.technique, poor wound care following implantation, or
intentional efforts to cause infection.
The incidence of infections involving CIEDs has steadily
increased over time, owing to a continually increasing
number of CIED recipients, longer cumulative time living
with CIEDs, and implantation in patients with risk factors
that predispose to infection. In a contemporary survey on the
incidence of CIED infections using a Nationwide Inpatient
Sample (NIS) discharge records query, Greenspon et al2
found an incidence of infection of 1.61% over a 16-year
period (1993–2008). The annual rate of infection rose
dramatically between 2004 and 2008 (1.53% in 2004 to
2.41% in 2008), coinciding with a substantial increase in
placement of implantable deﬁbrillators. With its associated
risks of signiﬁcant complications, morbidity, and mortality,
endocarditis is seen in approximately 10% of pacemaker-
related infections. Infection risk is further augmented in the
presence of recognized patient-related risk factors including
heart failure, renal dysfunction, diabetes mellitus, and
respiratory failure. Finally, it has also been demonstrated
that CIED explant owing to infection is substantially higher
with greater numbers of CIED-related procedures, including
generator replacement.3 The costs of managing CIED-related
infections, including long-duration antimicrobial therapy, hos-
pitalization, and invasive procedures including extractions and
CIED reimplantation, is nothing short of substantial.
Recurrent pocket infection in the same patient is an
unusual situation, particularly if guideline-based manage-
ment at the time of CIED infection is undertaken with
appropriate removal of infected hardware, appropriate dura-
tion of antimicrobial therapy, and appropriate timing of and
approach to CIED reimplantation. In general, with conﬁrmed
CIED pocket infections, removal of all implanted hardware
including leads is recommended, along with reimplantation
at an alternate site distant from the site of infection.1 In
addition to our patient’s condition, which predisposed to
signiﬁcant skin and soft tissue fragility as the dominant risk
341Chang and Doshi Leadless Pacemaker in Recurrent Infectionfactor for repeated infection, other conditions may also
predispose to a higher risk of repeated pocket infections,
including patients with CIEDs and extensive burn injury, as
well as immunocompromised and malnourished patients
with diminished skin integrity and increased risk of colo-
nization and secondary infection with unusual microorgan-
isms.4,5 In such patients, these conditions signiﬁcantly alter
natural, physical barrier protections against infection and
dramatically impair the systemic immune response to infe-
ction containment and treatment.
Implantation of the Nanostim leadless pacemaker is
currently performed in patients meeting a standard indication
for a VVI(R) pacemaker as outlined in the 2012 ACC/AHA/
HRS/ESC published guidelines.6 Early implant experience
has been favorable in terms of implant safety and success and
short-term follow-up of device performance.7 Off-label
implantation in this presented case was requested, as there
is no current recommended indication for the leadless
pacemaker in individuals with recurrent infections. While
there is insufﬁcient comparative data evaluating CIED
infections associated with traditional CIED implants (with
both epicardial and transvenous leads) vs the leadless pace-
maker, one would assume that the infection risk should be
substantially lower with the leadless device, given its lack of
direct communication and contact with subcutaneous tissue.
Dual-chamber pacing8–10 or even cardiac resynchronization
therapy, given depressed left ventricular ejection fraction,11
would be more ideal pacing strategies in the context of this
patient’s conduction disease. However, the leadless pace-
maker was considered to have the most ideal technological
properties to address the risk of recurrent infection in this
patient’s difﬁcult set of circumstances and to allow for
reliable, permanent pacing support.
There are approximately 200,000 new cases of infection
with M leprae or Hansen’s disease (leprosy) worldwide and
150 new cases in the United States annually. Infection
primarily involves the skin and peripheral nerves. Alterations
in local immune response in affected tissues, primarily in the
dermis, can cause “reactions” that result in the classic
cutaneous manifestations of the disease.12 We presume that
this is the underlying mechanism for this patient’s suscept-
ibility to CIED pocket infections.Conclusion
Progress in CIED technology has yielded devices that
can provide cardiac rhythm support with expectations of
minimizing or eliminating problems encountered with trans-
venous leads, including lead failure, venous obstruction, loss
or absence of venous access, and infection. While this case is
representative of a very small subset of patients, it demon-
strates an expanded opportunity for novel applications of
emerging CIED technology and will hopefully encourage
further development.
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